- Home
- BHVN vs GHRS Comparison
BHVN vs GHRS Comparison
Compare BHVN & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BHVN | GHRS |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BHVN | GHRS |
|---|---|---|
| Price | $13.75 | $18.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 10 |
| Target Price | $23.73 | ★ $42.89 |
| AVG Volume (30 Days) | ★ 3.0M | 303.0K |
| Earning Date | 10-29-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.99 | $12.04 |
| 52 Week High | $18.24 | $31.44 |
Technical Indicators
Market Signals| Indicator | BHVN | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 47.39 | 41.39 |
| Support Level | $13.56 | $17.54 |
| Resistance Level | $15.27 | $22.51 |
| Average True Range (ATR) | 1.00 | 1.32 |
| MACD | -0.12 | 0.12 |
| Stochastic Oscillator | 12.82 | 22.42 |
Price Performance
Historical ComparisonAbout BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.